Second Pivotal Trial Supports Lumateperone in Bipolar Mania

Johnson & Johnson reported November 10 that its second randomized Phase 3 bipolar-mania study met primary and key secondary endpoints. The result extends a prior positive study but lumateperone remains unapproved for mania.





